| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$219,027 ) |
| | 2023 | 2017 | TRAVERSE BIOSCIENCES INC. | 25 HEALTH SCIENCES DRIVE | STONY BROOK | NY | 11790-3350 | SUFFOLK | USA | R42DE024946 | Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease | 000 | 3 | NIH | 10/1/2022 | -$219,027 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2017 | TRAVERSE BIOSCIENCES INC. | 25 HEALTH SCIENCES DRIVE | STONY BROOK | NY | 11790-3350 | SUFFOLK | USA | R42DE024946 | Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease | 000 | 3 | NIH | 6/9/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = -$10,588 ) |
| | 2020 | 2017 | TRAVERSE BIOSCIENCES INC. | 25 HEALTH SCIENCES DRIVE | STONY BROOK | NY | 11790-3350 | SUFFOLK | USA | R42DE024946 | Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease | 000 | 3 | NIH | 9/23/2020 | $0 |
| | 2020 | 2014 | TRAVERSE BIOSCIENCES INC. | 25 HEALTH SCIENCES DRIVE | STONY BROOK | NY | 11790-3350 | SUFFOLK | USA | R41AG050021 | Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat | 000 | 1 | NIH | 10/1/2019 | -$10,588 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2017 | TRAVERSE BIOSCIENCES INC. | 25 HEALTH SCIENCES DRIVE | STONY BROOK | NY | 11790-3350 | SUFFOLK | USA | R42DE024946 | Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease | 000 | 3 | NIH | 8/29/2019 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $431,622 ) |
| | 2017 | 2017 | TRAVERSE BIOSCIENCES INC. | 25 HEALTH SCIENCES DRIVE | STONY BROOK | NY | 11790-3350 | SUFFOLK | USA | R42DE024946 | Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease | 000 | 3 | NIH | 8/3/2017 | $431,622 |
|
| Issue Date FY: 2016 ( Subtotal = $888,810 ) |
| | 2016 | 2016 | TRAVERSE BIOSCIENCES INC. | C/O CENTER FOR BIOTECHNOLOGY | STONY BROOK | NY | 11794 | SUFFOLK | USA | R42DE024946 | Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease | 000 | 2 | NIH | 8/4/2016 | $888,810 |
|
| Issue Date FY: 2015 ( Subtotal = $205,709 ) |
| | 2015 | 2015 | TRAVERSE BIOSCIENCES INC. | C/O CENTER FOR BIOTECHNOLOGY | STONY BROOK | NY | 11794 | SUFFOLK | USA | R41DE024946 | Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model | 000 | 1 | NIH | 1/23/2015 | $205,709 |
|
| Issue Date FY: 2014 ( Subtotal = $223,797 ) |
| | 2014 | 2014 | TRAVERSE BIOSCIENCES INC. | C/O CENTER FOR BIOTECHNOLOGY | STONY BROOK | NY | 11794 | SUFFOLK | USA | R41AG050021 | Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat | 000 | 1 | NIH | 7/28/2014 | $223,797 |
|
|
